[Immunotherapy for head and neck tumors : Updates from the 2024 ASCO Annual Meeting].
Immuntherapie von Kopf-Hals-Tumoren : Neuigkeiten von der ASCO-Jahresversammlung 2024.
Head and neck squamous cell carcinoma
Immune checkpoint inhibitors
Immunomodulation
Neoadjuvant therapy
Vaccine therapy
Journal
HNO
ISSN: 1433-0458
Titre abrégé: HNO
Pays: Germany
ID NLM: 2985099R
Informations de publication
Date de publication:
28 Oct 2024
28 Oct 2024
Historique:
accepted:
24
09
2024
medline:
28
10
2024
pubmed:
28
10
2024
entrez:
28
10
2024
Statut:
aheadofprint
Résumé
Immunotherapeutic approaches are now established in the treatment of various tumor entities, including head and neck squamous cell carcinoma (HNSCC). PD‑1 antibodies are currently approved for HNSCC with palliative intent but are increasingly being investigated in studies with curative objectives, e.g., as neoadjuvant therapy. At ASCO 2024, particular focus was placed on combinations of immunotherapy with therapeutic vaccines for human papillomavirus (HPV)-induced tumors. Moreover, the question of which patients benefit most from immunotherapy remains unresolved. The growing significance of PD-L1 expression, measured by the combined positive score (CPS), is becoming increasingly evident. This article summarizes the latest relevant findings from the largest international cancer congress, the American Society of Clinical Oncology (ASCO) 2024 Annual Meeting. Immuntherapeutische Ansätze haben mittlerweile einen festen Platz in der Behandlung verschiedenster Tumorentitäten, einschließlich der Plattenepithelkarzinome im Kopf-Hals-Bereich („head and neck squamous cell carcinoma“; HNSCC), eingenommen. Zugelassen sind PD-1-Antikörper für HNSCC nur in palliativer Intention, finden aber in Studien zunehmend auch Anwendung in kurativer Absicht, beispielsweise als neoadjuvante Therapie. Beim Kongress der American Society of Clinical Oncology (ASCO) 2024 standen insbesondere Kombinationen der Immuntherapie mit therapeutischen Impfungen bei durch humane Papillomaviren (HPV-)induzierten Tumoren im Fokus. Darüber hinaus stellt sich weiterhin die Frage, welche Patienten von der Immuntherapie profitieren. Es zeichnet sich insbesondere erneut die Bedeutung der PD-L1-Expression, gemessen als CPS (Combined Positive Score), ab. Im vorliegenden Artikel werden die neuen relevanten Erkenntnisse des größten internationalen Krebskongresses, der Jahresversammlung der ASCO 2024, zusammengefasst.
Autres résumés
Type: Publisher
(ger)
Immuntherapeutische Ansätze haben mittlerweile einen festen Platz in der Behandlung verschiedenster Tumorentitäten, einschließlich der Plattenepithelkarzinome im Kopf-Hals-Bereich („head and neck squamous cell carcinoma“; HNSCC), eingenommen. Zugelassen sind PD-1-Antikörper für HNSCC nur in palliativer Intention, finden aber in Studien zunehmend auch Anwendung in kurativer Absicht, beispielsweise als neoadjuvante Therapie. Beim Kongress der American Society of Clinical Oncology (ASCO) 2024 standen insbesondere Kombinationen der Immuntherapie mit therapeutischen Impfungen bei durch humane Papillomaviren (HPV-)induzierten Tumoren im Fokus. Darüber hinaus stellt sich weiterhin die Frage, welche Patienten von der Immuntherapie profitieren. Es zeichnet sich insbesondere erneut die Bedeutung der PD-L1-Expression, gemessen als CPS (Combined Positive Score), ab. Im vorliegenden Artikel werden die neuen relevanten Erkenntnisse des größten internationalen Krebskongresses, der Jahresversammlung der ASCO 2024, zusammengefasst.
Identifiants
pubmed: 39466338
doi: 10.1007/s00106-024-01524-w
pii: 10.1007/s00106-024-01524-w
doi:
Types de publication
English Abstract
Journal Article
Review
Langues
ger
Sous-ensembles de citation
IM
Informations de copyright
© 2024. The Author(s), under exclusive licence to Springer Medizin Verlag GmbH, ein Teil von Springer Nature.
Références
Bonner JA, Harari PM, Giralt J et al (2006) Radiotherapy plus cetuximab for squamous-cell carcinoma of the head and neck. N Engl J Med 354:567–578
doi: 10.1056/NEJMoa053422
pubmed: 16467544
Burtness B, Harrington KJ, Greil R et al (2019) Pembrolizumab alone or with chemotherapy versus cetuximab with chemotherapy for recurrent or metastatic squamous cell carcinoma of the head and neck (KEYNOTE-048): a randomised, open-label, phase 3 study. Lancet 394:1915–1928
doi: 10.1016/S0140-6736(19)32591-7
pubmed: 31679945
Butte MJ, Keir ME, Phamduy TB et al (2007) Programmed death‑1 ligand 1 interacts specifically with the B7‑1 costimulatory molecule to inhibit T cell responses. Immunity 27:111–122
doi: 10.1016/j.immuni.2007.05.016
pubmed: 17629517
pmcid: 2707944
Colevas AD, Chung CH, Adkins D et al (2024) A phase 1 dose-escalation and expansion study of CUE-101, given as monotherapy and in combination with pembrolizumab, in patients with recurrent/metastatic HPV16+ head and neck squamous cell cancer (R/M HNSCC). JCO 42:6004–6004
doi: 10.1200/JCO.2024.42.16_suppl.6004
Even C, Harrington KJ, Massarelli E et al (2024) Results of a randomized, double-blind, placebo-controlled, phase 2 study (OpcemISA) of the combination of ISA101b and cemiplimab versus cemiplimab for recurrent/metastatic (R/M) HPV16-positive oropharyngeal cancer (OPC). JCO 42:6003–6003
doi: 10.1200/JCO.2024.42.16_suppl.6003
Fayette J, Clatot F, Brana I et al (2024) Petosemtamab (MCLA-158) with pembrolizumab as first-line (1L) treatment of recurrent/metastatic (r/m) head and neck squamous cell carcinoma (HNSCC): Phase 2 study. JCO 42:6014–6014
doi: 10.1200/JCO.2024.42.16_suppl.6014
Ferrarotto R, Bell D, Rubin ML et al (2020) Impact of Neoadjuvant Durvalumab with or without Tremelimumab on CD8(+) Tumor Lymphocyte Density, Safety, and Efficacy in Patients with Oropharynx Cancer: CIAO Trial Results. Clin Cancer Res 26:3211–3219
doi: 10.1158/1078-0432.CCR-19-3977
pubmed: 32269052
pmcid: 8362306
Ferrarotto R, Bell D, Rubin ML et al (2019) Checkpoint inhibitors assessment in oropharynx cancer (CIAO): Safety and interim results. JCO 37:6008–6008
doi: 10.1200/JCO.2019.37.15_suppl.6008
Galon J, Bruni D (2019) Approaches to treat immune hot, altered and cold tumours with combination immunotherapies. Nat Rev Drug Discov 18:197–218
doi: 10.1038/s41573-018-0007-y
pubmed: 30610226
Ho AL, Nabell L, Neupane PC et al (2024) HB-200 arenavirus-based immunotherapy plus pembrolizumab as first-line treatment of patients with recurrent/metastatic HPV16-positive head and neck cancer: Updated results. JCO 42:6005–6005
doi: 10.1200/JCO.2024.42.16_suppl.6005
Karwacz K, Bricogne C, Macdonald D et al (2011) PD-L1 co-stimulation contributes to ligand-induced T cell receptor down-modulation on CD8+ T cells. EMBO Mol Med 3:581–592
doi: 10.1002/emmm.201100165
pubmed: 21739608
pmcid: 3191120
Kenter GG, Welters MJP, Valentijn ARPM et al (2009) Vaccination against HPV-16 oncoproteins for vulvar intraepithelial neoplasia. N Engl J Med 361:1838–1847
doi: 10.1056/NEJMoa0810097
pubmed: 19890126
Lee NY, Ferris RL, Psyrri A et al (2021) Avelumab plus standard-of-care chemoradiotherapy versus chemoradiotherapy alone in patients with locally advanced squamous cell carcinoma of the head and neck: a randomised, double-blind, placebo-controlled, multicentre, phase 3 trial. Lancet Oncol 22:450–462
doi: 10.1016/S1470-2045(20)30737-3
pubmed: 33794205
Leemans CR, Braakhuis BJ, Brakenhoff RH (2011) The molecular biology of head and neck cancer. Nat Rev Cancer 11:9–22
doi: 10.1038/nrc2982
pubmed: 21160525
Machiels JP, Tao Y, Licitra L et al (2024) Pembrolizumab plus concurrent chemoradiotherapy versus placebo plus concurrent chemoradiotherapy in patients with locally advanced squamous cell carcinoma of the head and neck (KEYNOTE-412): a randomised, double-blind, phase 3 trial. Lancet Oncol 25:572–587
doi: 10.1016/S1470-2045(24)00100-1
pubmed: 38561010
Massarelli E, William W, Johnson F et al (2019) Combining Immune Checkpoint Blockade and Tumor-Specific Vaccine for Patients With Incurable Human Papillomavirus 16-Related Cancer: A Phase 2 Clinical Trial. JAMA Oncol 5:67–73
doi: 10.1001/jamaoncol.2018.4051
pubmed: 30267032
Mcgrail D, Li K, Nipper A et al (2024) Neoadjuvant immunotherapy for oropharynx cancer: Correlative studies and long-term outcomes from the CIAO trial. JCO 42:6059–6059
doi: 10.1200/JCO.2024.42.16_suppl.6059
Mehra R, Cohen RB, Burtness BA (2008) The role of cetuximab for the treatment of squamous cell carcinoma of the head and neck. Clin Adv Hematol Oncol 6:742–750
pubmed: 18997665
pmcid: 2745918
Naara S, Yaniv D, Andrews C et al (2024) Intralesional nivolumab in oral potentially malignant disorders: A phase 1 pilot study on safety, tolerability, and preliminary efficacy. JCO 42:6016–6016
doi: 10.1200/JCO.2024.42.16_suppl.6016
Pearson AT, Seiwert TY, Cohen RB et al (2024) A randomized, double-blind, placebo-controlled phase II study of adjuvant pembrolizumab versus placebo in patients with head and neck squamous cell cancers at high risk for recurrence: The PATHWay study. JCO 42:6008–6008
doi: 10.1200/JCO.2024.42.16_suppl.6008
Rosenberg AJ, Juloori A, Izumchenko E et al (2024) Neoadjuvant HPV16-specific arenavirus-based immunotherapy HB-200 plus chemotherapy followed by response-stratified de-intensification in HPV16+ oropharyngeal cancer: TARGET-HPV. JCO 42:6017–6017
doi: 10.1200/JCO.2024.42.16_suppl.6017
Saba NF, Pamulapati S, Patel B, Mody M, Strojan P, Takes R, Mäkitie AA, Cohen O, Pace-Asciak P, Vermorken JB, Bradford C, Forastiere A, Teng Y, Wieland A, Ferlito A (2023) Novel Immunotherapeutic Approaches to Treating HPV-Related Head and Neck Cancer. Cancers (Basel). 15(7):1959. https://doi.org/10.3390/cancers15071959 . PMID: 37046621; PMCID: PMC10092986
Trivedi S, Srivastava RM, Concha-Benavente F et al (2016) Anti-EGFR Targeted Monoclonal Antibody Isotype Influences Antitumor Cellular Immunity in Head and Neck Cancer Patients. Clin Cancer Res 22:5229–5237
doi: 10.1158/1078-0432.CCR-15-2971
pubmed: 27217441
pmcid: 5093040
Van Poelgeest MI, Welters MJ, Van Esch EM et al (2013) HPV16 synthetic long peptide (HPV16-SLP) vaccination therapy of patients with advanced or recurrent HPV16-induced gynecological carcinoma, a phase II trial. J Transl Med 11:88
doi: 10.1186/1479-5876-11-88
pubmed: 23557172
pmcid: 3623745
Vermorken JB, Mesia R, Rivera F et al (2008) Platinum-based chemotherapy plus cetuximab in head and neck cancer. N Engl J Med 359:1116–1127
doi: 10.1056/NEJMoa0802656
pubmed: 18784101
Von Witzleben A, Wang C, Laban S et al (2020) HNSCC: Tumour Antigens and Their Targeting by Immunotherapy. Cells 9:
Welters MJ, Van Der Sluis TC, Van Meir H et al (2016) Vaccination during myeloid cell depletion by cancer chemotherapy fosters robust T cell responses. Sci Transl Med 8:334r
doi: 10.1126/scitranslmed.aad8307
Yan S, Chen S, Zhang X et al (2024) Neoadjuvant sintilimab and platinum-doublet chemotherapy followed by transoral robotic surgery for HPV-associated resectable oropharyngeal cancer: Single-arm, phase II trial. JCO 42:6011–6011
doi: 10.1200/JCO.2024.42.16_suppl.6011
Zandberg DP et al 856MO A randomized phase II study of concurrent vs. sequential pembrolizumab with chemoradiation (CRT) in locally advanced head and neck cancer (LA HNSCC): 4-year results and tumor-immune microenvironment analysis. Annals Oncol 34:S557–S558